Toward rapproachment in the placebo control debate: A Calculated Compromise of Power

Evaluation and the Health Professions

Volumn 26, Issue 4, 2003, Pages 404-414

  Leon, Andrew C ^a   Solomon, David A ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Clinical trial; Placebo; Power analysis; Sample size

Indexed keywords

PLACEBO;

ACUTE DISEASE; ALGORITHM; ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; HUMAN EXPERIMENT; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL ANALYSIS;

ALGORITHMS; CHI-SQUARE DISTRIBUTION; CONTROL GROUPS; ETHICS, RESEARCH; HUMANS; PATIENT SELECTION; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RESEARCHER-SUBJECT RELATIONS;

EID: 0242641574     PISSN: 01632787     EISSN: None     Source Type: Journal    
DOI: 10.1177/0163278703258106     Document Type: Article

References (19)

1. Applebaum, P. S., Roth, L. H., Lidz, C. W., Benson, P., & Winslade, W. (1987). False hopes and best data: Consent to research and the therapeutic misconception. Hastings Center Report, pp. 20-24.
2. Fleiss, J. L. (1981). Statistical methodsfor rates and proportions (2nd ed.). New York: John Wiley.
3. Friedman, L. M., Demets, D. L., & Furberg, D. L. (1998). Fundamentals of clinical trials (3rd ed.). New York: Springer-Verlag.
4. Klerman, G. L. (1986). Scientific and ethical considerations in the use of placebo controls in clinical trials in psychopharmacology. Psychopharmacology Bulletin, 22, 25-29.
5. Lavori, P. W., Sugarman J., Hays, M. T., & Feussner, J. R. (1999). Improving informed consent in clinical trials: A duty to experiment. Controlled Clinical Trials, 20, 187-193.
6. Leber, P. D. (1986). The placebo control in clinical trials (a view from the FDA). Psychopharmacology Bulletin, 22, 30-32.
7. Leber, P. D. (1986). The hazards of inference: The active control investigation. Epilepsia, 30, S57-S63.
8. Leon, A. C. (2001). Placebo controls can reduce exposure to risk: A power analytic perspective. Clinical Therapeutics, 23, 596-603.
9. Mill, J. S., & Bentham, J. (1987). Utilitarianism and other essays. New York: Penguin.
10. Office for Protection From Research Risks, Department of Health and Human Services, National Institutes of Health. Code of Federal Regulations, DHHS 45, CFR 46, Part 46.111, Protection Of Human Participants. Revised November 13, 2001.
11. Peduzzi, P., Guarino, P., Donta, S. T., Engel, C. C., Clauw, D. J., & Feussner, J. R. (2002). Research on informed consent: Investigator-developed versus focus group developed consent documents, a VA cooperative study. Controlled Clinical Trials, 23, 184-197.
12. Pocock, S. J. (1996). Clinical trials: A practical approach. New York: John Wiley.
13. Rothman, K. J., & Michels, K. B. (1994). The continuing unethical use of placebo controls. New England Journal of Medicine, 331, 394-398.
14. Spilker, B. (1991). Guide to clinical trials. New York: Raven.
15. Spriet, A., Dupin-Spriet, T., & Simon, P. (1994). Methodology of clinical drug trials (2nd ed.). New York: Karger.
16. Temple, R., & Etlenberg, S. S. (2000). Ptacebo-controtted trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Annals of Internal Medicine, 133, 455-463.
17. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. (1998, September). Guidance for industry: E9 statistical principles for clinical trials.
18. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. (2001, May). Guidance for industry: EIO choice of control group and related issues in clinical trials.
19. World Medical Association. (2000, October). Ethical principles for medical research involving human participants. Edinburgh, Scotland: 52nd WMA General Assembly.